Evidence map›Paper›PMID 27229905›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2016

An introduction to biomaterial-based strategies for curbing autoimmunity.

Jamal S Lewis, Riley P Allen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Latent, Immunosuppressive Nature of Poly(lactic-ACS biomaterials science & engineering · 2018
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jamal S LewisDepartment of Biomedical Engineering, University of California, Davis, CA 95616, USA jamlewis@ucdavis.edu.
Riley P AllenDepartment of Biomedical Engineering, University of California, Davis, CA 95616, USA.

Funding

Animal Models of Infectious Diseases Training ProgramT32AI060555 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI MCSORLEY, STEPHEN J · 2004 to 2025
$3.3M
Leveraging Engineering Approaches to understand Cryptococcal Vomocytosis from Immune CellsR35GM125012 · NIGMS · UNIVERSITY OF FLORIDA · PI Jamal S Lewis · 2017 to 2026
$3.2M
Particulate-based in vivo modulation for immunotherapy of Rheumatoid ArthritisR01AI139399 · NIAID · UNIVERSITY OF FLORIDA · PI LEWIS, JAMAL S · 2019 to 2023
$1.9M
Polymeric biomaterial-based microparticle vaccine for amelioration of Type 1 diabR43DK100132 · NIDDK · ONEVAX, LLC · PI LEWIS, JAMAL S · 2013 to 2013
$226k
NIAID NIH HHS R01 AI139399NIAID NIH HHS T32 AI060555NIDDK NIH HHS R43 DK100132NIGMS NIH HHS R35 GM125012
6 · The paper itself

Abstract

Recently, scientists have made significant progress in the development of immunotherapeutics that correct aberrant, autoimmune responses. Yet, concerns about the safety, efficacy, and wide scale applicability continue to hinder use of contemporary, immunology-based strategies. There is a clear need for therapies that finely control molecular and cellular elements of the immune system. Biomaterial engineers have taken up this challenge to develop therapeutics with selective spatial and temporal control of immune cells. In this review, we introduce the immunology of autoimmune disorders, survey the current therapeutic strategies for autoimmune diseases, and highlight the ongoing research efforts to engineer the immune system using biomaterials, for positive therapeutic outcomes in treatment of autoimmune disorders.

Indexed as

AnimalsAutoimmune DiseasesBiocompatible MaterialsHumansImmunologic FactorsImmunotherapyBiocompatible MaterialsImmunologic Factorsautoimmune diseasebiomaterialsImmuno-engineeringimmunotherapyparticulatetolerogenic

Identifiers

PMID27229905
PMCPMC4950372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.